JP2007502602A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2007502602A5 JP2007502602A5 JP2006523492A JP2006523492A JP2007502602A5 JP 2007502602 A5 JP2007502602 A5 JP 2007502602A5 JP 2006523492 A JP2006523492 A JP 2006523492A JP 2006523492 A JP2006523492 A JP 2006523492A JP 2007502602 A5 JP2007502602 A5 JP 2007502602A5
- Authority
- JP
- Japan
- Prior art keywords
- prostate
- composition
- vaccine construct
- subject
- polypeptide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2003904496A AU2003904496A0 (en) | 2003-08-21 | A novel vector | |
| PCT/AU2004/001129 WO2005019464A1 (en) | 2003-08-21 | 2004-08-20 | Poxvirus vector encoding prostate specific antigens for treatment of prostate cancer |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2007502602A JP2007502602A (ja) | 2007-02-15 |
| JP2007502602A5 true JP2007502602A5 (https=) | 2007-12-06 |
Family
ID=34200696
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006523492A Pending JP2007502602A (ja) | 2003-08-21 | 2004-08-20 | 前立腺癌の治療用の前立腺特異的抗原をコードするポックスウィルスベクター |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20070196346A1 (https=) |
| EP (1) | EP1660664A4 (https=) |
| JP (1) | JP2007502602A (https=) |
| AU (2) | AU2004267117B2 (https=) |
| CA (1) | CA2536317A1 (https=) |
| NZ (1) | NZ545438A (https=) |
| WO (1) | WO2005019464A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ601827A (en) * | 2007-10-18 | 2014-01-31 | Bavarian Nordic Inc | Use of mva to treat prostate cancer |
| US20150284444A1 (en) * | 2012-02-16 | 2015-10-08 | Masami Watanabe | Pharmaceutical composition for cancer treatment including fusion protein |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6165460A (en) * | 1995-07-10 | 2000-12-26 | Therion Biologics Corporation | Generation of immune responses to prostate-specific antigen (PSA) |
| CA2261989C (en) * | 1996-07-25 | 2008-09-30 | Therion Biologics Corporation | Recombinant pox virus for immunization against tumor-associated antigens |
| WO1998046769A1 (en) * | 1997-04-11 | 1998-10-22 | Dendreon Corporation | Composition and method for inducing an immune response against tumour-related antigens |
| EP1246646A2 (en) * | 2000-01-05 | 2002-10-09 | Aventis Pasteur Limited | Enhancing the immune response to an antigen by presensitizing with an inducing agent prior to immunizing with the inducing agent and the antigen |
| WO2002040059A2 (en) * | 2000-11-01 | 2002-05-23 | American Foundation For Biological Research, Inc. | Methods and compositions for inducing cell-mediated immune responses |
| US7247615B2 (en) * | 2001-11-30 | 2007-07-24 | United States Of America, Represented By The Secretary, Department Of Health And Human Services | Peptide agonists of prostate-specific antigen and uses therefor |
| US7179797B2 (en) * | 2002-09-27 | 2007-02-20 | Wisconsin Alumni Research Foundation | Methods and compositions for treating prostate cancer using DNA vaccines |
-
2004
- 2004-08-20 US US10/569,157 patent/US20070196346A1/en not_active Abandoned
- 2004-08-20 JP JP2006523492A patent/JP2007502602A/ja active Pending
- 2004-08-20 NZ NZ545438A patent/NZ545438A/en unknown
- 2004-08-20 CA CA002536317A patent/CA2536317A1/en not_active Abandoned
- 2004-08-20 EP EP04761166A patent/EP1660664A4/en not_active Ceased
- 2004-08-20 WO PCT/AU2004/001129 patent/WO2005019464A1/en not_active Ceased
- 2004-08-20 AU AU2004267117A patent/AU2004267117B2/en not_active Ceased
-
2011
- 2011-04-20 AU AU2011201813A patent/AU2011201813A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Cottingham et al. | Recombination-mediated genetic engineering of a bacterial artificial chromosome clone of modified vaccinia virus Ankara (MVA) | |
| US9951352B2 (en) | Poxvirus expression system | |
| ES2647662T3 (es) | Vacunas de ADN infeccioso frente al virus chikungunya | |
| Carroll et al. | Highly attenuated modified vaccinia virus Ankara (MVA) as an effective recombinant vector: a murine tumor model | |
| E Gomez et al. | MVA and NYVAC as vaccines against emergent infectious diseases and cancer | |
| JP6153473B2 (ja) | Ｂ型肝炎ウイルスコアタンパク質をコードする核酸分子およびそれを含むワクチン | |
| CN1266459A (zh) | 用于产生cd8t细胞免疫应答的接种方法和试剂 | |
| RU2014104360A (ru) | Мутантные полимеразы вируса гепатита в | |
| JP2010259446A5 (https=) | ||
| EP2391383B1 (en) | Codon-optimized hepatitis b virus core antigen (hbcag) | |
| CN107922981B (zh) | 用于增强在痘病毒中的表达的启动子 | |
| JP2013014588A (ja) | Ｍｖａの使用に基づくワクチン | |
| US20130045234A1 (en) | Neutralizing factors as vaccine adjuvants | |
| JP2021506300A (ja) | Ｂ型肝炎ウイルス（ｈｂｖ）に対する免疫応答を誘導するための方法および組成物 | |
| US6682742B1 (en) | Vector for integration of heterologous sequences into poxviral genomes | |
| CA2909225C (en) | Mutant vaccinia virus strains, uses thereof and method of producing the same | |
| CN1653182A (zh) | 重组禽痘病毒 | |
| JP2007502602A5 (https=) | ||
| RU2006145306A (ru) | Аденовирусный/альфавитный гибридный вектор для эффективного введения и экспрессии терапевтических генов в опухолевые клетки | |
| CN102000330B (zh) | 一种核酸疫苗佐剂及其构建方法 | |
| US7312202B2 (en) | Rationally designed and chemically synthesized promoter for genetic vaccine and gene therapy | |
| CN101965396A (zh) | 具有丙型肝炎病毒基因的重组痘苗病毒 | |
| Nemeckova et al. | Experimental therapy of HPV16 induced tumors with IL12 expressed by recombinant vaccinia virus in mice | |
| CN1357622A (zh) | 人白细胞白介素－12重组昆虫病毒株及其制备方法 | |
| JPWO2006013815A1 (ja) | ＨＣＶウイルスタンパク質をコードするＤＮＡを保有する組換えワクチニアウイルスＤＩｓ株、およびその利用 |